RA0814

antibody from Oursmab

Targeting: VIM

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0814

Provider

Oursmab

Product name

Burfiralimab (Biosimilar Reference Antibody) (VIM)

Antibody type

Monoclonal

Description

Burfiralimab (also known as hzVSF-v13) is a humanized IgG4 monoclonal antibody. It is designed as a broad-spectrum antiviral and anti-inflammatory agent. The antibody targets and binds to Vimentin expressed on the surface of virus-infected cells. By binding to Vimentin on these infected cells, Burfiralimab is thought to exert broad-spectrum antiviral activity through an unknown mechanism and also provide an anti-inflammatory effect, thereby mitigating the excessive inflammatory response caused by the viral infection. Due to its dual mechanism, Burfiralimab has been investigated in studies for severe viral infections such as severe COVID-19, aiming to suppress viral replication and alleviate life-threatening cytokine storm.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.